By Josh BeckermanInstil Bio Inc. shares were down 35% to $5.16 Friday afternoon. The company also said it will present findings from studies of anti-FOLR1 CoStAR T cells on June 5. Truist lowered its price target on the shares to $25 from $32. Analyst Asthika Goonewardene said Truist updated its model following the company's May 16 earnings report. Truist lowered its "peak 3L melanoma share" for the company to 20% from 30%.

Source: Wall Street Journal May 28, 2022 08:07 UTC